AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8053580
Drug: Thiopental infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental infusion rate of 40 mg/min
Trial: 8053580
Drug: Thiopental infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental infusion rate of 60 mg/min
Trial: 8053580
Drug: Thiopental infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental infusion rate of 75 mg/min
Trial: 8053580
Drug: Thiopental infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental infusion rate of 150 mg/min
Trial: 8053580
Drug: Thiopental infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental infusion rate of 300 mg/min
Trial: 8053580
Drug: Thiopental infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental infusion rate of 600 mg/min
Trial: 8053580
Drug: Thiopental infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental infusion rate of 1200 mg/min
Trial: 7431552
Drug: Erythromycin ophthalmic
RxNorm normalized name: erythromycin ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin ophthalmic ointment
Trial: 2922026
Drug: Tetracycline ophthalmic
RxNorm normalized name: oxytetracycline ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline ophthalmic ointment
Trial: 27434297
Drug: Nilotinib (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilotinib (both doses)
Trial: 27997805
Drug: High-Flow Nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Flow Nasal Cannula (HFNC) set at 40 L/min
Trial: 21154013
Drug: 30MIN (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30MIN (75 g isomaltulose, 75% reduced insulin dose)
Trial: 7499109
Drug: Pentosan polysulfate
RxNorm normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentosan polysulfate 22.5 mg/m2 every 6 hours
Trial: 7499109
Drug: Pentosan polysulfate
RxNorm normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentosan polysulfate 30 mg/m2 every 6 hours
Trial: 7499109
Drug: Pentosan polysulfate
RxNorm normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentosan polysulfate (various doses)
Trial: 1775522
Drug: Minaprine 200
RxNorm normalized name: minaprine
DrugBank: Minaprine (DB00805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minaprine 200 mg per day
Trial: 1775522
Drug: Minaprine 300
RxNorm normalized name: minaprine
DrugBank: Minaprine (DB00805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minaprine 300 mg per day
Trial: 9133750
Drug: Imipramine 150
RxNorm normalized name: imipramine pamoate 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine 150 mg per day
Trial: 27830357
Drug: Ulinastatin (10,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulinastatin (10,000 U/kg before anesthesia and 5000 U/kg daily on postoperative days 1 to 3)
Trial: 19694636
Drug: Celecoxib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (100 mg, n = 74)
Trial: 19694636
Drug: Diclofenac (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (50 mg, n = 69)
Trial: 17445350
Drug: Arachidonate-enriched TAG
RxNorm normalized name: arachidonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arachidonate-enriched TAG supplementation (838 mg ARA/d for 2 weeks)
Trial: 17445350
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (dietary intakes of arachidonic acid 179 (se13) mg/d)
Trial: 15451546
Drug: Deramciclane 30
RxNorm normalized name: Deramciclane
DrugBank: Deramciclane (DB06512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deramciclane 30 mg tablet administered after a high-fat meal
Trial: 15451546
Drug: Deramciclane 30
RxNorm normalized name: Deramciclane
DrugBank: Deramciclane (DB06512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deramciclane 30 mg tablet administered after an overnight fast
Trial: 30072135
Drug: PACRR scale
RxNorm normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PACRR scale (19-item scale) administered to physicians
Trial: 25641045
Drug: Olopatadine, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olopatadine, a second-generation antihistamine
Trial: 24228847
Drug: 200 mg/day
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day vitamin C for 3 months (group 1)
Trial: 24228847
Drug: 200 mg/day
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day vitamin C for 3 months (group 2)
Trial: 21864352
Drug: Non-operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-operative treatment with a sling
Trial: 16319603
Drug: Aggressive acid-suppressive
RxNorm normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive acid-suppressive therapy for 4 months
Trial: 8929247
Drug: Myrin tablets
RxNorm normalized name: Bio-Mycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myrin tablets (300 mg rifampicin, 150 mg isoniazid, 600 mg ethambutol HCl)
Trial: 8929247
Drug: Reference (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference (300 mg rifampicin, 200 mg isoniazid, 600 mg ethambutol HCl)
Trial: 1964020
Drug: Guar gum
RxNorm normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guar gum (31.7 g per day for 6 months)
Trial: 1964020
Drug: Soluble gums
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble gums (average of 19.5 g of added fiber per day for 4 weeks)
Trial: 23159524
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg BUP
Trial: 23159524
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg BUP
Trial: 21531237
Drug: Tailored behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored behavioral self-management intervention administered via telephone by a nurse every other month
Trial: 21531237
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of home blood pressure monitoring and tailored behavioral self-management intervention
Trial: 19704064
Drug: Six courses
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Six courses of paclitaxel 175 mg/m² every 3 weeks (maintenance)
Trial: 11758844
Drug: Gentamicin 2.0-2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin 2.0-2.5 mg/kg twice daily
Trial: 11758844
Drug: Gentamicin 4.0-5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin 4.0-5.0 mg/kg once daily
Trial: 9413851
Drug: Heparin-coated circuits
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated circuits (group H)
Trial: 29040231
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion through an OnQ pump
Trial: 27207739
Drug: Gel control
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gel control
Trial: 17640421
Drug: Tomato juice
RxNorm normalized name: TOMATO JUICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato juice without vitamin C (L)
Trial: 31621668
Drug: Dexmedetomidine (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (Group D) 1 μg/kg
Trial: 31621668
Drug: Esmolol (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (Group E) 2 mg/kg
Trial: 31621668
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dexmedetomidine and esmolol (Group DE) 0.5 μg/kg dexmedetomidine with 1 mg/kg esmolol
Trial: 22691110
Drug: Inhaled atropine
RxNorm normalized name: atropine sulfate Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled atropine sulfate via MicroDose Dry-Powder Inhaler (DPIA), 1.95 mg (5 doses × 0.4 mg per dose delivered over 12 min)
Trial: 22691110
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) atropine via auto-injector (AUTO), 2 mg
Trial: 18590586
Drug: Inulin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inulin (10 g/d) for 16 days
Trial: 11230611
Drug: oral trimethoprim/sulfamethoxazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral trimethoprim/sulfamethoxazole (TMP/SMX)
Trial: 11230611
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 1% PER and TMP/SMX
Trial: 9149675
Drug: CO inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO inhalation (1000 ppm for first 30 minutes, 100 ppm for last 30 minutes)
Trial: 9149675
Drug: Vehicle (room
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (room air inhalation)
Trial: 27756884
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (ACT) in stage II patients with high E2F score
Trial: 27756884
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (ACT) in stage II patients with low E2F score
Trial: 25539792
Drug: Pulmonary perfusion
RxNorm normalized name: Lobaria pulmonaria extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulmonary perfusion with oxygenated blood or Custodiol™ HTK solution
Trial: 25441486
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day soy isoflavone supplementation
Trial: 25441486
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg calcium carbonate (Control)
Trial: 20578658
Drug: Traditional buccal/palatal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional buccal/palatal injections
Trial: 14663900
Drug: Sorbilact infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorbilact infusion (twice a day for 4 days postoperatively)
Trial: 1387972
Drug: Hepaccine‐B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepaccine‐B vaccine (3 micrograms) at schedules of 0, 2, 6, 12 months
Trial: 1387972
Drug: Hepaccine‐B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepaccine‐B vaccine (3 micrograms) at schedules of 0, 1, 6, 12 months
Trial: 1387972
Drug: Hepaccine‐B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepaccine‐B vaccine (3 micrograms) at schedule of 0, 1, 2, 9 months
Trial: 1387972
Drug: Hevac‐B Pasteur
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hevac‐B Pasteur vaccine (5 micrograms) at schedule of 0, 1, 2, 9 months
Trial: 3885084
Drug: Tripotassium dicitrato-bismuthate
RxNorm normalized name: tripotassium glycyrrhizinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripotassium dicitrato-bismuthate tablet
Trial: 24712563
Drug: Synthetic human
RxNorm normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synthetic human GIP infusion with sitagliptin (inhibition of dipeptidyl peptidase 4)
Trial: 24712563
Drug: Synthetic human
RxNorm normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synthetic human GIP infusion with placebo
Trial: 24712563
Drug: Synthetic human
RxNorm normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synthetic human GLP‐1 infusion with sitagliptin (inhibition of dipeptidyl peptidase 4)
Trial: 24712563
Drug: Synthetic human
RxNorm normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synthetic human GLP‐1 infusion with placebo
Trial: 15571444
Drug: Qualitative group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qualitative group earned incentives for providing urines with concentrations <300 ng/ml
Trial: 11421506
Drug: Terbutaline Turbuhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline Turbuhaler 0.5 mg
Trial: 7506239
Drug: 0.05% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% chlorhexidine gluconate solution irrigation
Trial: 3030650
Drug: TFT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TFT plus one drop daily of rHu IFN-alpha 2 arg (30 million iu/ml)
Trial: 3030650
Drug: TFT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TFT plus rHu IFN-gamma (30 million iu/ml)
Trial: 3030650
Drug: TFT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TFT plus a mixture of alpha plus gamma (0.3 million iu/ml each)
Trial: 3030650
Drug: TFT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TFT plus a mixture of alpha plus gamma (1.5 million iu/ml each)
Trial: 3030650
Drug: Mixture of
RxNorm normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixture of alpha plus gamma at a moderate titer (1.5 million iu/ml each)
Trial: 31819304
Drug: Oral probiotics
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral probiotics (2x1 starting from the third postoperative day for 30 days, followed by 1x1 for two weeks each month for one year)
Trial: 28956773
Drug: Metoprolol (100±53
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (100±53 mg/d)
Trial: 18522686
Drug: HMB supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMB supplementation (300 mg HMB/kg feed)
Trial: 2942630
Drug: Acetaminophen with
RxNorm normalized name: acetaminophen with codeine ORAL ELIXIR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen with codeine (650 mg plus 60 mg every 4 to 6 hours)
Trial: 2942630
Drug: Diflunisal (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflunisal (1,000 mg initially then 500 mg twice a day)
Trial: 31500602
Drug: Enhanced treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced treatment as usual (TAU+)
Trial: 31888765
Drug: Incentive spirometer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incentive spirometer therapy (IS)
Trial: 31888765
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no IS therapy)
Trial: 24119064
Drug: 10% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% carbamide peroxide gel with fluoride and potassium nitrate
Trial: 24119064
Drug: 10% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% carbamide peroxide gel without desensitizers
Trial: 23062408
Drug: Xueshuantong Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xueshuantong Injection (175 mg/d)
Trial: 11489752
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of lycopene twice daily for 3 weeks
Trial: 9703292
Drug: Finasteride 5
RxNorm normalized name: finasteride 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride 5 mg day(-1) for 12 months
Trial: 31987958
Drug: Ultrahypofractionated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrahypofractionated radiation therapy
Trial: 31987958
Drug: Increasing dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing dose per fraction in the experimental arm
Trial: 31987958
Drug: Biochemical control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biochemical control at doses above approximately 80 Gy
Trial: 20232750
Drug: Malaria vaccine
RxNorm normalized name: malaria vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Malaria vaccine development
Trial: 20232750
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of control measures (e.g., drugs, larvicides, clearing breeding sites)
Trial: 3277608
Drug: Concurrent controls
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent controls
Trial: 11314876
Drug: Daily left
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily left prefrontal repetitive transcranial magnetic stimulation (rTMS) for 2 weeks (total of 16,000 stimuli)
Trial: 9771414
Drug: 0.9% sodium
RxNorm normalized name: LMD with 0.9% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride solution
Trial: 30378768
Drug: Family-based behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based behavioural weight loss treatment (FBT)
Trial: 29205515
Drug: Yoga training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga training (three 1-hour sessions weekly for 1 year)
Trial: 29205515
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no intervention, monitored monthly)
Trial: 22257997
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no ethyl chloride spray)
Trial: 22257997
Drug: Before skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before skin preparation
Trial: 22257997
Drug: After skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After skin preparation but before application of ethyl chloride
Trial: 17651076
Drug: 1.5 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g/day soyoligosaccharide intake (LSO)
Trial: 17651076
Drug: 3 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/day soyoligosaccharide intake (HSO)
Trial: 16324022
Drug: Propofol administered
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol administered at a rate of 20 mg.30 s(‐1) (i.e. 40 mg.min(‐1)) until BIS value reached 35‐45; Group CP required lower dosage of propofol for induction (P = 0.03).
Trial: 9435364
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline solution at a rate of 1000 ml/h
Trial: 9435364
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline solution at a rate of 500 ml/h
Trial: 8387966
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg twice daily for the first day, followed by 500 mg once daily for four days)
Trial: 8387966
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg twice daily for 14 days)
Trial: 3814200
Drug: Cyclosporine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (10 mg/kg/day)
Trial: 3814200
Drug: Azathioprine (2.5‐3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (2.5‐3 mg/kg/day)
Trial: 31656130
Drug: Sucralose (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralose (8 × 5 g packets/day)
Trial: 31656130
Drug: Steviol glycosides
RxNorm normalized name: Steviol Glycosides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steviol glycosides (4 × 1 g packets/day)
Trial: 31656130
Drug: Sucrose (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose (8 × 5 g packets/day)
Trial: 28746153
Drug: Intravenous Patient-Controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Patient-Controlled Analgesia (IV-PCA)
Trial: 25251249
Drug: Virtual reality-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality-based rehabilitation combined with conventional occupational therapy (30 mins/session for 9 sessions)
Trial: 25251249
Drug: Conventional occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional occupational therapy (30 mins/session for 15 sessions)
Trial: 19228530
Drug: E75 peptide
RxNorm normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E75 peptide vaccine plus granulocyte-macrophage colony-stimulating factor
Trial: 19228530
Drug: E75 peptide
RxNorm normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E75 peptide vaccine
Trial: 19228530
Drug: E75 peptide
RxNorm normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E75 peptide vaccine (excluding 3 patients with PSA recurrences during vaccine series)
Trial: 15232762
Drug: Elective preterm
RxNorm normalized name: hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elective preterm delivery with management plan including high-resolution ultrasound, weekly re-evaluation, corticosteroids, and delivery if bowel compromise present > 30 weeks
Trial: 9433369
Drug: Fexofenadine 120
RxNorm normalized name: fexofenadine hydrochloride 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine 120 mg once daily
Trial: 10929922
Drug: Loratadine 10
RxNorm normalized name: loratadine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loratadine 10 mg once daily
Trial: 8491949
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (local nasal immunotherapy with macronized powder extract)
Trial: 3434850
Drug: Dexamethasone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (4 mg) tablets
Trial: 27863331
Drug: Inpatient enhanced
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient enhanced cognitive behavioural therapy for eating disorders (CBT-E)